Pregnancy outcome among HIV-infected women on different antiretroviral therapies in Ethiopia: a cohort study
Objective The objective of the study was to compare pregnancy outcomes according to maternal antiretroviral treatment (ART) regimens.Design A retrospective cohort study.Participants and settings Clinical data was extracted from ART exposed pregnancies of HIV-infected Ethiopian women attending antena...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-08-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/9/8/e027344.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective The objective of the study was to compare pregnancy outcomes according to maternal antiretroviral treatment (ART) regimens.Design A retrospective cohort study.Participants and settings Clinical data was extracted from ART exposed pregnancies of HIV-infected Ethiopian women attending antenatal care follow-up in public health facilities in Addis Ababa between February 2010 and October 2016.Outcomes The primary outcomes evaluated were preterm birth, low birth weight and small-for-gestational-age.Results A total 1663 of pregnancies exposed to ART were included in the analyses. Of these pregnancies, 17% resulted in a preterm birth, 19% in low birth weight and 32% in a small-for-gestational-age baby. Compared with highly active antiretroviral therapy (HAART) initiated during pregnancy, zidovudine monotherapy was less likely to result in preterm birth (adjusted OR 0.35, 95% CI 0.19 to 0.64) and low birth weight (adjusted OR 0.48, 95% CI 0.24 to 0.94). We observed no differential risk of preterm birth, low birth weight and small-for-gestational-age, when comparing women who initiated HAART during pregnancy to women who initiated HAART before conception. The risk for preterm birth was higher in pregnancies exposed to nevirapine-based HAART (adjusted OR 1.44, 95% CI 1.06 to 1.96) compared with pregnancies exposed to efavirenz-based HAART. Comparing nevirapine-based HAART with efavirenz-based HAART indicated no strong evidence of increased risk of low birth weight or small-for-gestational-age.Conclusions We observed a higher risk of preterm birth among women who initiated HAART during pregnancy compared with zidovudine monotherapy. Pregnancies exposed to nevirapine-based HAART also had a greater risk of preterm births compared with efavirenz-based HAART. |
|---|---|
| ISSN: | 2044-6055 |